Intracisternally localized bacterial DNA containing CpG motifs induces meningitis.
Unmethylated CpG motifs are frequently found in bacterial DNA, and have recently been shown to exert immunostimulatory effects on leukocytes. Since bacterial infections in the CNS will lead to local release of prokaryotic DNA, we wanted to investigate whether such an event might trigger meningitis. To that end, we have intracisternally injected mice and rats with bacterial DNA and oligonucleotides containing CpG motifs. Histopathological signs of meningitis were evident within 12 h and lasted for at least 14 days, and were characterized by an influx of monocytic, Mac-3(+) cells and by a lack of T lymphocytes. To study the mechanisms whereby unmethylated CpG DNA gives rise to meningitis, we deleted the monocyte/macrophage population leading to abrogation of brain inflammation. Also, interaction with NF-kappaB using antisense technology led to down-regulation of proinflammatory cytokine production and frequency of meningitis. Furthermore, specific interactions with vascular selectin expression and inhibition of NO synthase led to a significant amelioration of meningitis, altogether indicating that this condition is dependent on macrophages and their products. In contrast, neutrophils, NK cells, T/B lymphocytes, IL-12, and complement system were not instrumental in meningitis triggered by bacterial DNA containing CpG motifs. This study proves that bacterial DNA containing unmethylated CpG motifs induces meningitis, and indicates that this condition is mediated in vivo by activated macrophages.
Deng
G M
GM
Department of Rheumatology, Göteborg University, Göteborg, Sweden. guo-min@rheuma.gu.se
Liu
Z Q
ZQ
Tarkowski
A
A
D000276:Adjuvants, Immunologic / Q000009:adverse effects*; D000818:Animals; D002555:Cerebrospinal Fluid / Q000166:cytology; D018925:Chemokines / Q000378:metabolism; D003165:Complement System Proteins / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D016373:DNA, Antisense / Q000627:therapeutic use; D004269:DNA, Bacterial / Q000009:adverse effects* / Q000276:immunology*; D004357:Drug Synergism; D008070:Lipopolysaccharides / Q000009:adverse effects; D008264:Macrophages / Q000276:immunology; D008578:Meninges / Q000473:pathology; D008581:Meningitis / Q000188:drug therapy / Q000209:etiology*; D051379:Mice; D008815:Mice, Inbred Strains; D018345:Mice, Knockout; D009000:Monocytes / Q000276:immunology; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D009838:Oligodeoxyribonucleotides / Q000276:immunology*; D010457:Peptidoglycan / Q000009:adverse effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D019087:Selectins / Q000378:metabolism
D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D018925:Chemokines; D016207:Cytokines; D016373:DNA, Antisense; D004269:DNA, Bacterial; D008070:Lipopolysaccharides; D016328:NF-kappa B; D009838:Oligodeoxyribonucleotides; D010457:Peptidoglycan; D019087:Selectins; D009569:Nitric Oxide; D003165:Complement System Proteins